Suppr超能文献

上皮性卵巢癌中的炎性微环境:Toll样受体4、髓样分化因子88及相关蛋白的作用

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

作者信息

Li Zheng, Block Matthew S, Vierkant Robert A, Fogarty Zachary C, Winham Stacey J, Visscher Daniel W, Kalli Kimberly R, Wang Chen, Goode Ellen L

出版信息

Tumour Biol. 2016 Oct;37(10):13279-13286. doi: 10.1007/s13277-016-5163-2. Epub 2016 Jul 26.

Abstract

The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7-1.8], both strong HR 2.1 [95 % CI 1.1-3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

摘要

肿瘤相关炎性微环境可能在上皮性卵巢癌(EOC)的致癌作用及预后中发挥关键作用,但需要对源自患者的肿瘤进行详细分析。在此,我们使用免疫组织化学染色研究了500多名EOC患者肿瘤中TLR4和MyD88相关标志物的表达。我们证明,TLR4和MyD88的高表达预示着EOC患者较差的总生存期;最有可能的是,这归因于它们与浆液性组织学以及高肿瘤负荷和侵袭性特征(包括手术分期、分级和腹水)相关。即使在进行协变量调整后,TLR4和MyD88的联合表达似乎仍是缩短生存时间的独立危险因素(中度表达时HR均为1.1 [95% CI 0.7 - 1.8],强表达时HR均为2.1 [95% CI 1.1 - 3.8],弱表达时作为参照;p = 0.027)。我们发现,在TLR4和MyD88表达均升高且NF-κB信号通路激活的EOC组织中,hsp60、hsp70、β2防御素和HMGB1的表达也增加。总体而言,这些结果表明内源性配体激活TLR4/MyD88/NF-κB信号可能促成一种炎性微环境,从而导致EOC患者出现更具侵袭性的表型和更差的临床结局。

相似文献

1
The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Tumour Biol. 2016 Oct;37(10):13279-13286. doi: 10.1007/s13277-016-5163-2. Epub 2016 Jul 26.
2
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.
World J Surg Oncol. 2012 Sep 17;10:193. doi: 10.1186/1477-7819-10-193.
5
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014.
6
Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Int J Biochem Cell Biol. 2015 Apr;61:90-102. doi: 10.1016/j.biocel.2015.02.001. Epub 2015 Feb 11.
8
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

引用本文的文献

1
Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review.
Medicine (Baltimore). 2025 Jun 13;104(24):e42857. doi: 10.1097/MD.0000000000042857.
2
Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia.
J Clin Lab Anal. 2025 Jun;39(12):e70055. doi: 10.1002/jcla.70055. Epub 2025 Jun 7.
4
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
PLoS One. 2024 Dec 2;19(12):e0314564. doi: 10.1371/journal.pone.0314564. eCollection 2024.
6
High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.
Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229.
9
The emerging roles of TLR and cGAS signaling in tumorigenesis and progression of ovarian cancer.
Front Pharmacol. 2022 Dec 16;13:1072670. doi: 10.3389/fphar.2022.1072670. eCollection 2022.
10
Helicobacter Pylori and Gastric Cancer Progression.
Curr Microbiol. 2022 Nov 3;79(12):383. doi: 10.1007/s00284-022-03089-9.

本文引用的文献

2
Toll-like receptors: Activation, signalling and transcriptional modulation.
Cytokine. 2015 Aug;74(2):181-9. doi: 10.1016/j.cyto.2015.02.025. Epub 2015 Apr 3.
3
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
4
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.
Front Immunol. 2014 Jul 22;5:341. doi: 10.3389/fimmu.2014.00341. eCollection 2014.
5
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014.
6
TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma .
Oncol Lett. 2014 Mar;7(3):871-877. doi: 10.3892/ol.2013.1759. Epub 2013 Dec 16.
7
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23.
8
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.
J Transl Med. 2013 Jun 13;11:147. doi: 10.1186/1479-5876-11-147.
9
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.
World J Surg Oncol. 2012 Sep 17;10:193. doi: 10.1186/1477-7819-10-193.
10
Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.
J Transl Med. 2012 Apr 25;10:77. doi: 10.1186/1479-5876-10-77.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验